Bio-Light Updates Phase II Results of OBE101

According to Globes Online, an Israeli business daily, Bio-Light Israeli Life Sciences Investments reported results from its subsidiary’s Phase II clinical trial in the U.S. of OBE101, a treatment of obesity indicated statistically significant results for weight loss among certain women aged 50 or less.

Earlier this month, the subsidiary, OBEcure, reported that initial results indicated that OBE101 was ineffective. Although patients lost weight, the loss was statistically insignificant compared with the control group, Globes reported.

Recent results indicate that variables such as age, gender and ethnic origin have a statistically significant effect on weight loss. The segment of the subpopulation of women ages 50 and under showed that a certain dosage caused substantial weight loss compared with the control group, the paper added.

In this subpopulation, except for women of Hispanic descent, weight loss was the most statistically significant among patients taking high dosage of OBE101, compared with the control group.

In view of the latest findings, OBEcure said it intends to pursue additional clinical trials of the drug.